Increased SET expression is found in CML, where it correlates with blast crisis and resistance to therapeutic BCR/ABL tyrosine kinase inhibitors (TKI) (82), in Philadelphia chromosome-positive (Ph)-ALL (133), (c-KIT positive) AML (113, 134), and B-CLL (85). Here, SET is linked to chronic myelogenous leukemia, BCR-ABL1 positive.